ITM hopes to Compete against Lutathera
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Protagonist Verifies Takeda’s interest
Rusfertide, the subject of a 2024 tie-up, scores in phase 3.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
